Safety
SAEs, infection, scabies
SCABIES, HEAD LICE, ADVERSE EVENTS, BEDBUGS, INFECTIONS, INFECTION, INFESTATION
Rate of AEs and serious adverse events (SAEs) and the difference between ivermectin and albendazole.Secondary
Complementary efficacy analysis methodsT﻿ime to first positive RDT in children in the cohortMolecular force of infection in a subset of children in the cohortMalaria case incidence in all ages presenting at a health facilityMalaria prevalence in all ages one month after the last doseMultiplicity of infection in all ages one month after the last dose
Complementary safety variablesObserved tolerability of the doseRate of SUSARsAEs and SAEs by organ system
PharmacokineticsWhole blood concentrations of ivermectin in dried blood spots.
Impact of ivermectin against selected ectoparasites and NTDs in the dosage regimen chosenSerial prevalence of scabies using a simplified version of the algorithm described by Mahe et al. [Serial prevalence of head lice by visual inspection over three minutes in scalp sites of predilection for head lice: the back of the ears, temples, and neck [Serial prevalence of Tunga penetrans via visual inspection of the skin in both feet and applying the Fortaleza scale [Serial prevalence and severity of bed bug infestation by direct questions about bedbugs in the house, and visual inspection of exposed skin and sleeping rooms for evidence of bed bug bites or bed bug infestation.
Prevalence - incidence correlationMalaria infection incidence in children (under 5 years) in the pediatric active cohort at community and health facility levelsMalaria prevalence at all ages
Relationship between active and passive surveillanceInfection incidence in children at the community level (active surveillance)Infection incidence in children at the health facility level (passive surveillance)
Performance of RDTs vs PCRResults correlation between HRP2 and pLDH-based RDTsResults correlation between RDTs and PCRProportion of RDT-negative but PCR-positive infections